Evidence map›Paper›PMID 37610511›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Metal-Organic Frameworks Nucleated by Silk Fibroin and Modified with Tumor-Targeting Peptides for Targeted Multimodal Cancer Therapy.

Yuping Chen, Ruyin Lyu, Jie Wang, Qichao Cheng, Yanfang Yu, Shuxu Yang, Chuanbin Mao, Mingying Yang

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Metal-Ligand Complexes as Multifunctional Platforms for Photo-Activated Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  10. Article
  11. Review
  12. Biomedical Applications of Metal-Organic Frameworks Revisited.Industrial & engineering chemistry research · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Yuping ChenInstitute of Applied Bioresource Research, College of Animal Science, Zhejiang University, Yuhangtang Road 866, Hangzhou, Zhejiang, 310058, P. R. China.
Ruyin LyuInstitute of Applied Bioresource Research, College of Animal Science, Zhejiang University, Yuhangtang Road 866, Hangzhou, Zhejiang, 310058, P. R. China.
Jie WangInstitute of Applied Bioresource Research, College of Animal Science, Zhejiang University, Yuhangtang Road 866, Hangzhou, Zhejiang, 310058, P. R. China.
Qichao ChengInstitute of Applied Bioresource Research, College of Animal Science, Zhejiang University, Yuhangtang Road 866, Hangzhou, Zhejiang, 310058, P. R. China.
Yanfang YuJiangxi Cash Crops Institute, Nanchang, Jiangxi, 330202, P. R. China.
Shuxu YangDepartment of Neurosurgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, P. R. China.
Chuanbin MaoDepartment of Biomedical Engineering, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, P. R. China.ORCID 0000-0002-8142-3659
Mingying YangInstitute of Applied Bioresource Research, College of Animal Science, Zhejiang University, Yuhangtang Road 866, Hangzhou, Zhejiang, 310058, P. R. China.
Zhejiang University · CNChinese University of Hong Kong · HKJiangxi Academy of Agricultural Sciences · CNSir Run Run Shaw Hospital · CN

Funding

eZhejiang Provincial Science and Technology Plans 2021C02072-3eZhejiang Provincial Science and Technology Plans 2021C02072-6National Natural Science Foundation of China 32101095National Natural Science Foundation of China 81871499National Natural Science Foundation of China 81911530223National Postdoctoral Science Foundation of China 2022M722714Plan of National and Zhejiang Provincial Youth Science and Technology Innovation leader 2018R52021Plan of National and Zhejiang Provincial Youth Science and Technology Innovation leader [2020]366Provincial Key Laboratory Construction Plans 2020E10025State of Sericulture Industry Technology System CARS-18-ZJ0501Technology Innovation Guidance Project of Jiangxi Province 20212BDH81028Zhejiang Provincial Science and Technology Plan 2021C02072-3Zhejiang Provincial Science and Technology Plan 2021C02072-6
6 · The paper itself

Abstract

Multimodal therapy requires effective drug carriers that can deliver multiple drugs to specific locations in a controlled manner. Here, the study presents a novel nanoplatform constructed using zeolitic imidazolate framework-8 (ZIF-8), a nanoscale metal-organic framework nucleated under the mediation of silk fibroin (SF). The nanoplatform is modified with the newly discovered MCF-7 breast tumor-targeting peptide, AREYGTRFSLIGGYR (AR peptide). Indocyanine green (ICG) and doxorubicin (DOX) are loaded onto the nanoplatform with high drug encapsulation efficiency (>95%). ICG enables the resultant nanoparticles (NPs), called AR-ZS/ID-P, to release reactive oxygen species for photodynamic therapy (PDT) and heat for photothermal therapy (PTT) under near-infrared (NIR) irradiation, promoting NIR fluorescence and thermal imaging to guide DOX-induced chemotherapy. Additionally, the controlled release of both ICG and DOX at acidic tumor conditions due to the dissolution of ZIF-8 provides a drug-targeting mechanism in addition to the AR peptide. When intravenously injected, AR-ZS/ID-P NPs specifically target breast tumors and exhibit higher anticancer efficacy than other groups through ICG-enabled PDT and PTT and DOX-derived chemotherapy, without inducing side effects. The results demonstrate that AR-ZS/ID-P NPs are a promising multimodal theranostic nanoplatform with maximal therapeutic efficacy and minimal side effects for targeted and controllable drug delivery.

Indexed as

Breast NeoplasmsFibroinsMetal-Organic FrameworksPeptidesAnimalsCombined Modality TherapyDoxorubicinDrug CarriersDrug Delivery SystemsFemaleHumansIndocyanine GreenMCF-7 CellsMiceNanoparticlesPhotochemotherapyDoxorubicinDrug CarriersFibroinsIndocyanine GreenMetal-Organic FrameworksPeptidesBombyx mori (B. mori) silk fibroindrug carriertriple therapeutic effectstumor-targeting peptidezeolitic imidazolate framework-8 (ZIF-8)

Identifiers

PMID37610511
PMCPMC10558676
OpenAlexW4386083808

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.